COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

被引:0
作者
Masataka Nishiga
Dao Wen Wang
Yaling Han
David B. Lewis
Joseph C. Wu
机构
[1] Stanford Cardiovascular Institute,Department of Medicine
[2] Division of Cardiovascular Medicine,Division of Cardiology, Department of Internal Medicine
[3] Stanford University School of Medicine,Division of Allergy, Immunology, and Rheumatology, Department of Pediatrics
[4] Tongji Hospital,Department of Radiology
[5] Tongji Medical College,undefined
[6] Huazhong University of Science & Technology,undefined
[7] Cardiovascular Research Institute,undefined
[8] Department of Cardiology,undefined
[9] General Hospital of Northern Theater Command,undefined
[10] Stanford University School of Medicine,undefined
[11] Stanford University School of Medicine,undefined
来源
Nature Reviews Cardiology | 2020年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global pandemic that has affected the lives of billions of individuals. Extensive studies have revealed that SARS-CoV-2 shares many biological features with SARS-CoV, the zoonotic virus that caused the 2002 outbreak of severe acute respiratory syndrome, including the system of cell entry, which is triggered by binding of the viral spike protein to angiotensin-converting enzyme 2. Clinical studies have also reported an association between COVID-19 and cardiovascular disease. Pre-existing cardiovascular disease seems to be linked with worse outcomes and increased risk of death in patients with COVID-19, whereas COVID-19 itself can also induce myocardial injury, arrhythmia, acute coronary syndrome and venous thromboembolism. Potential drug–disease interactions affecting patients with COVID-19 and comorbid cardiovascular diseases are also becoming a serious concern. In this Review, we summarize the current understanding of COVID-19 from basic mechanisms to clinical perspectives, focusing on the interaction between COVID-19 and the cardiovascular system. By combining our knowledge of the biological features of the virus with clinical findings, we can improve our understanding of the potential mechanisms underlying COVID-19, paving the way towards the development of preventative and therapeutic solutions.
引用
收藏
页码:543 / 558
页数:15
相关论文
共 266 条
  • [51] Gomez X(2020)ST-elevation myocardial infarction in patients with COVID-19: clinical and angiographic outcomes Circulation 114 1852-1418
  • [52] Gonzalez-Martinez C(2020)Suspected myocardial injury in patients with COVID-19: evidence from front-line clinical observation in Wuhan, China Int. J. Cardiol. 114 1417-2872
  • [53] Wilkinson N(2019)Chinese Society of Cardiology expert consensus statement on the diagnosis and treatment of adult fulminant myocarditis Sci. China Life Sci. 395 2871-89
  • [54] Theocharis P(2020)Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19) JAMA Cardiol. 75 88-2088
  • [55] Yin W(2020)Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin Eur. Heart J. 383 2083-514
  • [56] Dai W(2020)Pathological findings of COVID-19 associated with acute respiratory distress syndrome Lancet Respir. Med. 41 m1091-450
  • [57] Cui J(2020)Myocardial localization of coronavirus in COVID-19 cardiogenic shock Eur. J. Heart Fail. 368 512-732
  • [58] Li F(2020)Autopsy findings and venous thromboembolism in patients with COVID-19 Ann. Intern. Med. 8 427-1936
  • [59] Shi ZL(2020)Postmortem examination of patients with COVID-19 JAMA 17 730-1153
  • [60] Du L(2014)Angiotensin-converting enzyme 2 and angiotensin 1–7: novel therapeutic targets Nat. Rev. Cardiol. 39 1930-1031